Autopsy report · NCT04608812

Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection

“Slow enrollment and financial constraints.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 2 years before it stopped.
• 7 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

OncoSynergy, Inc.

Sponsor type

Industry

Conditions

Glioma, Malignant; High Grade Glioma; Glioblastoma; Glioblastoma Multiforme; Anaplastic Astrocytoma

Interventions

OS2966; Gadoteridol

Participants

7

Sites

1

Countries

United States

Trials that died the same way

• Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity
  “Slow enrollment and financial issues” (94% match in meaning)
• A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC
  “Slow enrollment.” (88% match in meaning)
• Lumbar Disc Herniation Outcome Measures
  “Slow/low enrollment” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.